Efficacy of BRAF-Inhibitor Therapy in BRAF
Dabrafenib
Histiocytosis
Targeted therapy
Vemurafenib
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
01
07
2020
accepted:
04
09
2020
pubmed:
29
9
2020
medline:
22
6
2021
entrez:
28
9
2020
Statut:
ppublish
Résumé
Langerhans cell histiocytosis (LCH) is a rare histiocytic neoplasm. To date, there is a lack of U.S. Food and Drug Administration-approved treatments in adult LCH to establish optimal first-line therapy. We conducted a retrospective, single-center case series evaluating the use of BRAF inhibitors in adult patients with BRAF
Identifiants
pubmed: 32985015
doi: 10.1002/onco.13541
pmc: PMC7938396
doi:
Substances chimiques
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1001-1004Subventions
Organisme : NCI NIH HHS
ID : P30 CA086862
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA097274
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA097422
Pays : United States
Informations de copyright
© AlphaMed Press 2020.
Références
Hepatol Int. 2010 Aug 04;4(3):653-8
pubmed: 21063491
Blood. 2020 Apr 16;135(16):1319-1331
pubmed: 32106306
JAMA Oncol. 2017 Sep 1;3(9):1253-1256
pubmed: 28253394
JAMA Oncol. 2018 Mar 1;4(3):384-388
pubmed: 29188284
Blood. 2017 Sep 14;130(11):1377-1380
pubmed: 28667012
Blood Adv. 2018 Aug 28;2(16):2156-2158
pubmed: 30154124
J Natl Compr Canc Netw. 2015 Jun;13(6):715-8
pubmed: 26085387
J Am Acad Dermatol. 2014 Sep;71(3):e97-9
pubmed: 25128147
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384
Lancet Oncol. 2014 Mar;15(3):323-32
pubmed: 24508103
Blood. 2010 Sep 16;116(11):1919-23
pubmed: 20519626